Chemicals · Founded 2003 · www.cleanscience.co.in · BSE 543318 · NSE CLEAN · ISIN INE227W01023
No Notes Added Yet
Business
Clean Science And Technology Ltd. is an Indian specialty chemical manufacturer. The company is primarily engaged in the manufacturing of functionally critical specialty chemicals such as Performance Chemicals, Pharmaceutical Intermediates, and FMCG Chemicals. They focus on developing innovative and eco-friendly manufacturing processes that are largely backward integrated, allowing for cost-effective production and reduced waste. The core business model revolves around R&D-driven process innovation to produce high-value, niche chemicals for various end-user industries globally. They make money by selling these specialized chemical products to B2B customers in sectors like pharmaceuticals, agrochemicals, plastics, paints, and personal care.
Revenue Mix
The company's product portfolio is broadly categorized into:
Performance Chemicals: Includes MEHQ, BHA, AP, 4-MAP, etc., used as inhibitors, antioxidants, and UV stabilizers in various industrial applications like polymers, paints, and coatings.
Pharmaceutical Intermediates: Products like Guaiacol and its derivatives, crucial raw materials for pharmaceutical active pharmaceutical ingredients (APIs).
FMCG Chemicals: Primarily includes D-Limonene based products and other additives used in consumer goods, flavors, and fragrances.
While specific revenue contributions are not provided here, the company has established global leadership in several niche performance chemicals like MEHQ, BHA, and AP.
Industry
Clean Science operates in the global specialty chemicals industry, which is characterized by niche product markets, strong R&D focus, and high barriers to entry for specific applications. The Indian specialty chemicals sector is growing, benefiting from global supply chain diversification ("China plus one" strategy) and increasing domestic demand. Clean Science holds a leading global position in several of its key products (e.g., MEHQ, BHA, AP), primarily due to its proprietary, cost-effective, and environmentally sustainable manufacturing processes. It competes with both global and domestic specialty chemical players, often differentiating itself through process efficiency and product quality.
MOAT
Clean Science possesses several durable competitive advantages:
Proprietary Process Innovation: The company has developed non-conventional, environmentally friendly, and proprietary manufacturing processes for many of its products, leading to higher yields, lower costs, and reduced waste compared to traditional methods.
Cost Leadership: Resulting directly from its process innovation, Clean Science often has a significant cost advantage over competitors in its niche product categories.
Backward Integration: Strategic backward integration into key raw materials for some products enhances supply chain security, cost control, and quality consistency.
High Switching Costs: For B2B specialty chemicals, customers typically undergo rigorous approval processes, leading to high switching costs once a supplier and product formulation are established.
R&D Focus: Continuous investment in R&D ensures ongoing process improvements and new product development, sustaining its competitive edge.
Growth Drivers
Global Demand for Specialty Chemicals: Increasing demand from various end-user industries (pharmaceuticals, agrochemicals, polymers) globally, especially in emerging markets.
Import Substitution & "China Plus One": India's push for self-reliance and global supply chain diversification can drive demand for domestic specialty chemical manufacturers.
Capacity Expansion: Ongoing and planned capital expenditure projects to increase production capacity for existing and new products.
New Product Development & Diversification: Expansion into new chemical categories and applications, and catering to a broader range of industries like electronics, water treatment, and food additives.
Sustainability Trends: The company's focus on green chemistry and environmentally friendly processes aligns with global sustainability trends, potentially opening new opportunities.
Risks
Raw Material Price Volatility: Fluctuations in the prices and availability of key raw materials can impact margins, despite backward integration efforts.
Intense Competition: While leading in niches, the specialty chemicals market is competitive, with potential threats from new entrants or aggressive pricing by existing players, particularly from China.
Environmental & Regulatory Risks: Stringent environmental regulations and compliance requirements, both domestic and international, can lead to increased operational costs or potential penalties.
Technological Obsolescence: The risk of new technologies or alternative processes emerging that could render current proprietary processes less competitive.
Currency Fluctuations: Being an exporter, the company is exposed to foreign exchange rate movements, which can affect profitability.
End-User Industry Cyclicality: Demand is tied to the health and growth of various end-user industries, making it susceptible to economic slowdowns in those sectors.
Management & Ownership
Clean Science And Technology is a promoter-led company, founded by the Ranka family. The management team has a strong focus on research & development, process engineering, and operational excellence, which has been instrumental in building its niche leadership. The promoters maintain a significant ownership stake, aligning their interests with long-term company performance. Post-IPO, the ownership structure also includes institutional investors and public shareholders.
Outlook
Clean Science And Technology is well-positioned in the growing specialty chemicals sector, benefiting from its strong R&D capabilities and proprietary, cost-efficient manufacturing processes. Its leadership in several niche product categories and ongoing capacity expansions suggest a positive growth trajectory driven by increasing global demand and import substitution trends. However, the company operates in a competitive and somewhat cyclical industry. Key challenges include managing raw material price volatility, navigating evolving environmental regulations, and sustaining its innovation edge against global competitors. The ability to successfully execute expansion plans, diversify its product portfolio, and maintain its cost leadership will be crucial for its sustained performance.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 195 | 228 | 224 | 238 | 241 | 264 | 243 | 245 | 220 | 249 |
| Other Income | 8 | 14 | 10 | 11 | 5 | 12 | 13 | 7 | 10 | 3 |
| Total Income | 203 | 242 | 234 | 249 | 246 | 276 | 256 | 251 | 229 | 252 |
| Total Expenditure | 108 | 133 | 129 | 148 | 142 | 159 | 143 | 158 | 147 | 153 |
| Operating Profit | 94 | 109 | 105 | 101 | 104 | 117 | 113 | 94 | 82 | 99 |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 11 | 13 | 16 | 18 | 18 | 17 | 19 | 19 | 19 | 21 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 83 | 95 | 89 | 83 | 85 | 100 | 95 | 75 | 63 | 78 |
| Provision for Tax | 20 | 25 | 23 | 24 | 20 | 25 | 24 | 19 | 17 | 19 |
| Profit After Tax | 63 | 70 | 66 | 59 | 66 | 74 | 70 | 55 | 46 | 58 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 63 | 70 | 66 | 59 | 66 | 74 | 70 | 55 | 46 | 58 |
| Adjusted Earnings Per Share | 5.9 | 6.6 | 6.2 | 5.5 | 6.2 | 7 | 6.6 | 5.2 | 4.3 | 5.5 |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Dec 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 241 | 393 | 419 | 0 | 512 | 685 | 936 | 791 | 967 | 957 |
| Other Income | 5 | 11 | 11 | 0 | 26 | 30 | 30 | 41 | 39 | 33 |
| Total Income | 246 | 405 | 430 | 0 | 538 | 715 | 966 | 833 | 1005 | 988 |
| Total Expenditure | 167 | 257 | 234 | 0 | 253 | 385 | 533 | 459 | 579 | 601 |
| Operating Profit | 78 | 148 | 196 | 0 | 285 | 330 | 432 | 374 | 427 | 388 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| Depreciation | 8 | 11 | 14 | 0 | 17 | 25 | 36 | 46 | 69 | 78 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 70 | 137 | 182 | 0 | 267 | 305 | 396 | 327 | 357 | 311 |
| Provision for Tax | 21 | 39 | 43 | 0 | 69 | 76 | 100 | 82 | 92 | 79 |
| Profit After Tax | 49 | 98 | 140 | 0 | 198 | 228 | 295 | 244 | 264 | 229 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 49 | 98 | 140 | 0 | 198 | 228 | 295 | 244 | 264 | 229 |
| Adjusted Earnings Per Share | 4.3 | 8.6 | 13.1 | 0 | 18.7 | 21.5 | 27.8 | 23 | 24.9 | 21.6 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 22% | 12% | 0% | 0% |
| Operating Profit CAGR | 14% | 9% | 0% | 0% |
| PAT CAGR | 8% | 5% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -49% | -18% | NA% | NA% |
| ROE Average | 20% | 25% | 31% | 34% |
| ROCE Average | 27% | 34% | 42% | 46% |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Dec 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 188 | 272 | 342 | 0 | 540 | 768 | 1010 | 1203 | 1416 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 10 | 14 | 11 | 0 | 18 | 21 | 26 | 32 | 28 |
| Total Current Liabilities | 38 | 41 | 77 | 0 | 102 | 135 | 116 | 236 | 251 |
| Total Liabilities | 236 | 327 | 430 | 0 | 660 | 925 | 1152 | 1472 | 1695 |
| Fixed Assets | 102 | 127 | 166 | 0 | 186 | 296 | 460 | 636 | 715 |
| Other Non-Current Assets | 9 | 8 | 7 | 0 | 79 | 59 | 61 | 101 | 86 |
| Total Current Assets | 125 | 193 | 257 | 0 | 395 | 559 | 630 | 735 | 895 |
| Total Assets | 236 | 327 | 430 | 0 | 660 | 925 | 1152 | 1472 | 1695 |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Dec 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 6 | 30 | 9 | 0 | 9 | 9 | 58 | 12 | 10 |
| Cash Flow from Operating Activities | 45 | 85 | 160 | 0 | 193 | 127 | 279 | 236 | 214 |
| Cash Flow from Investing Activities | -18 | -95 | -106 | 0 | -187 | -79 | -270 | -185 | -152 |
| Cash Flow from Financing Activities | -5 | -11 | -55 | 0 | -6 | -0 | -55 | -53 | -53 |
| Net Cash Inflow / Outflow | 22 | -21 | -2 | 0 | 0 | 49 | -45 | -2 | 10 |
| Closing Cash & Cash Equivalent | 30 | 9 | 9 | 0 | 9 | 58 | 12 | 10 | 20 |
| # | Mar 2018 | Mar 2019 | Mar 2020 | Dec 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 4.32 | 8.62 | 13.14 | 0 | 18.68 | 21.51 | 27.78 | 22.97 | 24.88 |
| CEPS(Rs) | 4.99 | 9.59 | 14.43 | 0 | 20.3 | 23.86 | 31.18 | 27.29 | 31.38 |
| DPS(Rs) | 3 | 7.5 | 9 | 0 | 2.5 | 3.25 | 5 | 5 | 6 |
| Book NAV/Share(Rs) | 16.58 | 24.02 | 32.2 | 0 | 50.81 | 72.3 | 94.95 | 113.02 | 133.08 |
| Core EBITDA Margin(%) | 30.44 | 34.74 | 44.26 | 0 | 50.58 | 43.83 | 43.01 | 42 | 40.14 |
| EBIT Margin(%) | 29.18 | 34.8 | 43.58 | 0 | 52.23 | 44.57 | 42.34 | 41.41 | 36.99 |
| Pre Tax Margin(%) | 28.95 | 34.72 | 43.48 | 0 | 52.16 | 44.5 | 42.28 | 41.25 | 36.9 |
| PAT Margin (%) | 20.15 | 24.83 | 33.3 | 0 | 38.71 | 33.36 | 31.54 | 30.83 | 27.35 |
| Cash Profit Margin (%) | 23.28 | 27.64 | 36.57 | 0 | 42.07 | 37 | 35.4 | 36.63 | 34.5 |
| ROA(%) | 20.71 | 34.66 | 36.87 | 0 | 36.41 | 28.84 | 28.43 | 18.6 | 16.7 |
| ROE(%) | 26.03 | 42.47 | 45.47 | 0 | 45 | 34.95 | 33.23 | 22.09 | 20.22 |
| ROCE(%) | 37.58 | 59.11 | 59 | 0 | 60.5 | 46.65 | 44.55 | 29.62 | 27.3 |
| Receivable days | 59.65 | 46.14 | 56.41 | 0 | 51.31 | 60.69 | 58.46 | 71.46 | 69.31 |
| Inventory Days | 43.67 | 30.66 | 31.17 | 0 | 31.16 | 37.58 | 38.41 | 53.6 | 51.56 |
| Payable days | 84.98 | 51.96 | 81.94 | 0 | 142.77 | 132.49 | 102.25 | 122.63 | 106.46 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 92.65 | 45.51 | 57.83 | 46.91 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 27.57 | 13.32 | 11.75 | 8.77 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0.16 | 0.4 | 0.38 | 0.51 |
| EV/Net Sales(x) | -0.11 | -0.01 | -0.01 | 0 | -0.01 | 30.8 | 14.34 | 17.82 | 12.81 |
| EV/Core EBITDA(x) | -0.35 | -0.04 | -0.03 | 0 | -0.02 | 63.9 | 31.04 | 37.73 | 29.03 |
| Net Sales Growth(%) | 0 | 63.13 | 6.62 | 0 | 22.21 | 33.66 | 36.64 | -15.42 | 22.13 |
| EBIT Growth(%) | 0 | 93.28 | 33.51 | 0 | 46.46 | 14.05 | 29.8 | -17.27 | 9.09 |
| PAT Growth(%) | 0 | 99.72 | 42.98 | 0 | 42.07 | 15.18 | 29.18 | -17.33 | 8.35 |
| EPS Growth(%) | 0 | 99.72 | 52.45 | 0 | 42.1 | 15.18 | 29.16 | -17.34 | 8.33 |
| Debt/Equity(x) | 0 | 0.01 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio(x) | 3.31 | 4.68 | 3.34 | 0 | 3.87 | 4.15 | 5.46 | 3.11 | 3.56 |
| Quick Ratio(x) | 2.54 | 3.78 | 2.89 | 0 | 3.36 | 3.49 | 4.52 | 2.59 | 2.97 |
| Interest Cover(x) | 125.56 | 411.02 | 443.51 | 0 | 820.94 | 687.48 | 710.02 | 257.48 | 424.67 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.98 | 74.98 | 74.98 | 74.97 | 74.97 | 74.97 | 74.97 | 50.97 | 50.96 | 51.29 |
| FII | 5.92 | 5.88 | 6.06 | 5.83 | 5.98 | 6.07 | 6.21 | 11.14 | 10 | 13.39 |
| DII | 5.14 | 5.04 | 4.55 | 4.77 | 5.46 | 5.76 | 5.92 | 18.98 | 19.77 | 17.16 |
| Public | 13.97 | 14.1 | 14.42 | 14.43 | 13.6 | 13.2 | 12.9 | 18.92 | 19.26 | 18.16 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 7.97 | 7.97 | 7.97 | 7.97 | 7.97 | 7.97 | 7.97 | 5.42 | 5.42 | 5.45 |
| FII | 0.63 | 0.63 | 0.64 | 0.62 | 0.64 | 0.64 | 0.66 | 1.18 | 1.06 | 1.42 |
| DII | 0.55 | 0.54 | 0.48 | 0.51 | 0.58 | 0.61 | 0.63 | 2.02 | 2.1 | 1.82 |
| Public | 1.48 | 1.5 | 1.53 | 1.53 | 1.44 | 1.4 | 1.37 | 2.01 | 2.05 | 1.93 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10.62 | 10.63 | 10.63 | 10.63 | 10.63 | 10.63 | 10.63 | 10.63 | 10.63 | 10.63 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +22% | +12% | — | — |
| Operating Profit CAGR | +14% | +9% | — | — |
| PAT CAGR | +8% | +5% | — | — |
| Share Price CAGR | -49% | -18% | — | — |
| ROE Average | +20% | +25% | +31% | +34% |
| ROCE Average | +27% | +34% | +42% | +46% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.98 | 74.98 | 74.98 | 74.97 | 74.97 | 74.97 | 74.97 | 50.97 | 50.96 | 51.29 |
| FII | 5.92 | 5.88 | 6.06 | 5.83 | 5.98 | 6.07 | 6.21 | 11.14 | 10 | 13.39 |
| DII | 5.14 | 5.04 | 4.55 | 4.77 | 5.46 | 5.76 | 5.92 | 18.98 | 19.77 | 17.16 |
| Public | 25.02 | 25.02 | 25.02 | 25.03 | 25.03 | 25.03 | 25.03 | 49.03 | 49.04 | 48.71 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 7.97 | 7.97 | 7.97 | 7.97 | 7.97 | 7.97 | 7.97 | 5.42 | 5.42 | 5.45 |
| FII | 0.63 | 0.63 | 0.64 | 0.62 | 0.64 | 0.64 | 0.66 | 1.18 | 1.06 | 1.42 |
| DII | 0.55 | 0.54 | 0.48 | 0.51 | 0.58 | 0.61 | 0.63 | 2.02 | 2.1 | 1.82 |
| Public | 2.66 | 2.66 | 2.66 | 2.66 | 2.66 | 2.66 | 2.66 | 5.21 | 5.21 | 5.18 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10.62 | 10.63 | 10.63 | 10.63 | 10.63 | 10.63 | 10.63 | 10.63 | 10.63 | 10.63 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.